This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Grifols, S.A.

Drug Names(s): ARD-3100, CFL, Liposomally Encapsulated ciprofloxacin for Inhalation

Description: Lipoquin (CFI, ARD-3100) is a liposomal formulation of ciprofloxacin.

Deal Structure: Aradigm and Grifols
In May 2013, Grifols and Aradigm signed an exclusive, worldwide license for Aradigm's inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory disease, including non-cystic fibrosis bronchiectasis (BE). Under the terms of agreement, the companies will advance the formulations into Phase III clinical trials in BE. Grifols will be responsible for all development and clinical expenses up to a maximum of $65 million for the BE indication. Aradigm is entitled to receive cash payments of up to $25 million upon achievement of development milestones. Grifols is responsible for all commercialization activities and will pay Aradigm tiered royalties on worldwide sales of products utilizing Aradigm's proprietary inhaled ciprofloxacin formulations. Grifols will be granted an option to license Aradigm's AERx pulmonary drug delivery platform for use with another molecule.

Partners: Aradigm Corporation

Lipoquin News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug